Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 nm » 5 mm (Expand Search), 5 cm (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 nm » 5 mm (Expand Search), 5 cm (Expand Search)
-
761
-
762
-
763
Galiellalactone decreases the proportion of ALDH+ prostate cancer cells in vitro and the ALDH1A1 expression in vivo.
Published 2013“…<p>A. DU145 and LNCaP-IL6 cells were treated with galiellalactone (5–50 µM) for 24 h and subjected to ALDEFLUOR® assay. …”
-
764
Algorithm operation steps.
Published 2025“…Experimental results demonstrate that SCI-YOLO11 achieves a 3.2% improvement over baseline models in terms of MAP@0.5 metric; precision and recall rates increase by 2.6% and 3.7%, respectively. …”
-
765
-
766
-
767
-
768
-
769
-
770
-
771
-
772
-
773
-
774
-
775
-
776
-
777
-
778
-
779
Structure-Based Design of a Chemical Probe Set for the 5‑HT<sub>5A</sub> Serotonin Receptor
Published 2022“…Docking over 6 million molecules against a 5-HT<sub>5A</sub>R homology model identified 5 mid-μM ligands, one of which was optimized to <b>UCSF678</b>, a 42 nM arrestin-biased partial agonist at the 5-HT<sub>5A</sub>R with a more restricted off-target profile and decreased assay liabilities versus SB-699551. …”
-
780
Structure-Based Design of a Chemical Probe Set for the 5‑HT<sub>5A</sub> Serotonin Receptor
Published 2022“…Docking over 6 million molecules against a 5-HT<sub>5A</sub>R homology model identified 5 mid-μM ligands, one of which was optimized to <b>UCSF678</b>, a 42 nM arrestin-biased partial agonist at the 5-HT<sub>5A</sub>R with a more restricted off-target profile and decreased assay liabilities versus SB-699551. …”